- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Rahway Today
By the People, for the People
Merck Initiates Pivotal Trial for Investigational Tie2 Bispecific
The pharmaceutical giant is testing a new cancer treatment in late-stage clinical trials.
Apr. 2, 2026 at 12:10pm
Got story updates? Submit your updates here. ›
Merck has announced the initiation of a pivotal Phase 2b/3 clinical trial evaluating its investigational bispecific Tie2 agonist MK-8748, also known as Tiespectus, for the treatment of certain types of cancer. The trial will assess the safety and efficacy of the drug candidate in patients with advanced solid tumors.
Why it matters
Tie2 agonists represent a novel approach to cancer treatment, with the potential to stimulate the Tie2 receptor and activate the body's own vascular and immune systems to fight tumor growth. If successful, MK-8748 could provide a new therapeutic option for patients with advanced cancers.
The details
The pivotal Phase 2b/3 trial will evaluate the safety and efficacy of MK-8748 in patients with advanced solid tumors. The trial will assess the drug's ability to shrink tumors and improve overall survival. Merck plans to enroll approximately 800 patients at sites across North America, Europe, and Asia.
- Merck announced the initiation of the pivotal trial on April 2, 2026.
The players
Merck
A leading global pharmaceutical company that develops and markets a wide range of medicines, vaccines, and other healthcare products.
MK-8748 (Tiespectus)
Merck's investigational bispecific Tie2 agonist, which is being evaluated for the treatment of advanced solid tumors.
What’s next
Merck expects to complete enrollment for the pivotal trial by the end of 2027 and report topline results in 2029.
The takeaway
The initiation of this pivotal trial for MK-8748 represents an important milestone in Merck's efforts to develop innovative cancer treatments that harness the body's own vascular and immune systems. If successful, this bispecific Tie2 agonist could provide a new therapeutic option for patients with advanced solid tumors.
